Drug addiction is a chronic, relapsing brain disorder whose epidemiology, neurobiology, and responsiveness to treatment place it firmly within the domain of public health rather than criminal justice. Analyzing the structural failures of the criminalization model, this discussion draws on evidence from addiction neuroscience, harm reduction research, and comparative drug policy to argue that incarceration is not merely ineffective against addiction — it is a categorical mismatch for the condition it purports to address. Evidence-based interventions including medication-assisted treatment, syringe services programs, and naloxone distribution consistently reduce mortality and improve social functioning in ways that prosecution cannot replicate. The Portuguese decriminalization model is examined as a cautionary example: decarceration succeeds only when paired with robust treatment infrastructure. Undergraduate students in public health, criminal justice, sociology, and political science will find this analysis useful for understanding how policy frameworks shape health outcomes and what a health-centered approach to addiction would require in practice.
The dominant American response to drug addiction for most of the twentieth century rested on a single, largely unexamined premise: that people who use drugs are making a moral choice, and that punishment can reverse that choice. This premise shaped everything from mandatory minimum sentencing to the rhetorical framing of the "War on Drugs." Yet a growing body of epidemiological, neurological, and public health research has made the premise untenable. The more analytically precise argument is not simply that addiction deserves compassion, though it does, but that the criminal justice framework is structurally incompatible with the nature of addiction itself. Addiction is a chronic, relapsing brain disorder whose etiology, trajectory, and responsiveness to intervention share far more with diseases like hypertension or type 2 diabetes than with deliberate criminal conduct. Treating it through incarceration does not address its pathology; it simply relocates suffering while foreclosing the therapeutic interventions that epidemiology shows to be effective. This essay argues that the shift from a criminal justice to a public health framework is not merely a matter of political preference but is demanded by what the evidence actually says about how addiction works, who it affects, and what measurably reduces its harms.
Understanding why the criminal justice framework fails requires first grasping the epidemiological landscape of addiction in the United States. The scale of the problem is difficult to overstate. According to the Substance Abuse and Mental Health Services Administration, roughly 46 million Americans aged twelve or older met the diagnostic criteria for a substance use disorder in 2021. The opioid epidemic alone has claimed more than 500,000 lives since 1999, a toll that surpasses American combat deaths in World War II. These numbers are not distributed randomly across the population. Addiction clusters along the fault lines of poverty, unemployment, trauma exposure, housing instability, and racial marginalization — a pattern that epidemiologists recognize as characteristic of socially determined health outcomes (Galea and Vlahov 36). The significance of this clustering is interpretive, not merely descriptive: it tells us that addiction is produced by conditions, not just by individual will. When researchers map overdose death rates against indicators of economic distress, the correlation is consistent enough that economists Anne Case and Angus Deaton coined the phrase "deaths of despair" to describe opioid, alcohol, and suicide mortality as a single syndrome expressing social dislocation rather than personal failure (Case and Deaton 4). A criminal justice framework is simply not designed to address despair. Courts can impose sentences; they cannot undo the structural conditions that make drug use a rational — if catastrophic — response to unrelenting hardship.
The neurobiological evidence reinforces this epidemiological picture by explaining the mechanism through which social vulnerability becomes compulsive behavior. Addiction produces measurable changes in the brain's dopaminergic reward circuitry, the prefrontal cortex regions responsible for impulse control and decision-making, and the stress response systems of the amygdala. These changes are not metaphorical; they are visible on neuroimaging and persist long after active drug use has stopped, which is precisely why relapse rates for opioid use disorder without treatment approach 80 to 90 percent. The American Society of Addiction Medicine, the National Institute on Drug Abuse, and the American Medical Association have all formally classified addiction as a chronic brain disorder, not a moral failing (McLellan et al. 1689). This classification has direct policy implications. Chronic diseases require ongoing management, not one-time punishment. The expectation that incarceration will produce lasting behavioral change in someone whose brain circuitry has been altered by addiction is as scientifically indefensible as expecting a prison sentence to cure hypertension. Criminalization, in this light, is not a misguided policy choice — it is a categorical error, a solution applied to a problem it cannot diagnose.
"Medication-assisted treatment reduces mortality significantly"
"Syringe programs and naloxone save lives pragmatically"
"Decriminalization requires treatment investment to succeed"
What the evidence ultimately reveals is that the criminal justice approach to addiction has not failed merely in the sense of producing poor outcomes, though it has done that too. It has failed at the level of concept. Addiction is not a crime that happens to produce health consequences; it is a health condition that sometimes produces legal ones. The policy implications follow from this reordering of priorities: expand medication-assisted treatment access, fund syringe services and naloxone distribution, pilot supervised consumption facilities, and redirect prosecutorial resources toward structural interventions rather than personal possession. These are not radical proposals — they are the standard practice of every high-income country that has reduced its drug mortality rates below those of the United States. Drug policy reform in this direction does not require abandoning moral concern for people affected by addiction; it requires locating that concern in a framework capable of actually acting on it. The difference between treating addiction as sin and treating it as sickness is not a difference in compassion. It is a difference in what the data can teach us and whether we are willing to learn.
You’re 50% through this paper. Sign up to read the remaining 3 sections.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.